Ascendis Pharma A/S (ASND)

Ascendis Pharma Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Net Income	741.76	-228.03	-378.08	-481.45	-583.19	-383.58
Depreciation & Amortization	17.14	17.21	17.25	18.43	17.51	14.95
Other Amortization	0.49	0.49	0.47	0.48	0.44	0.45
Loss (Gain) From Sale of Assets	0.02	-	-0.09	0.01	0.02	-
Asset Writedown & Restructuring Costs	-2.23	5.28	-	7.83	-	-
Loss (Gain) on Equity Investments	12.59	-16.31	20.06	18.4	17.7	-12.04
Stock-Based Compensation	120.56	116.17	95.51	66.66	64.18	66.83
Other Operating Activities	-531.1	88.13	45.85	2.07	0.11	-56.53
Change in Accounts Receivable	-95.51	15.59	-118.61	-32.77	-11.53	-6.66
Change in Inventory	-7.19	-5.92	-86.68	-78.26	-55.27	-75.41
Change in Accounts Payable	23.84	-10.37	26.97	3.55	45.94	39.19
Change in Unearned Revenue	0.3	0.13	-1.2	-7.08	8.65	5.2
Change in Other Net Operating Assets	68.85	71.53	72.36	14.77	-0.26	-10.05
Operating Cash Flow	349.51	53.9	-306.2	-467.36	-495.7	-417.65
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Capital Expenditures	-14.39	-8.49	-1.43	-2.44	-14.49	-23.7
Sale of Property, Plant & Equipment	-	-	0.95	0.05	-	-
Sale (Purchase) of Intangibles	-	-	-	-	-	-0.53
Investment in Securities	-	-	7.35	288.87	66.69	-86.35
Other Investing Activities	-	-	-	-	9.54	-
Investing Cash Flow	-13.05	-8.49	6.88	286.47	61.73	-110.58

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Long-Term Debt Issued	-	-	134.16	136.26	503.28	-
Long-Term Debt Repaid	-	-21.96	-11.37	-10.44	-6.36	-6.43
Net Debt Issued (Repaid)	-30.13	-21.96	122.79	125.82	496.93	-6.43
Issuance of Common Stock	110.86	87.08	340.43	10.29	5.15	379.42
Repurchase of Common Stock	-116.19	-28.79	-	-1.81	-105.31	-21.61
Other Financing Activities	-0.13	-	-19.29	-	-	-
Financing Cash Flow	-35.58	36.33	443.93	134.29	396.77	351.39

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Foreign Exchange Rate Adjustments	17.33	-25.24	22.77	-6.01	35.69	38.59
Net Cash Flow	318.21	56.5	167.38	-52.6	-1.5	-138.25

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Free Cash Flow	335.12	45.41	-307.62	-469.8	-510.19	-441.35
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	32.01%	6.31%	-84.60%	-176.14%	-996.97%	-5674.38%
Free Cash Flow Per Share	5.29	0.75	-5.31	-8.35	-9.10	-8.06
Levered Free Cash Flow	12.77	164.71	-200.32	-332.95	-156.42	-281.9
Unlevered Free Cash Flow	93.02	215.12	-159.38	-305.41	-137.24	-279.45

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash Interest Paid	30.36	22.94	15.21	15.67	9.29	1.84
Cash Income Tax Paid	7.92	6.68	5.51	4.47	0	-0.15
Change in Working Capital	-9.71	70.96	-107.16	-99.79	-12.47	-47.72

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 15, 2026

Data Sources Report a data error